ChemicalBook CAS DataBase List Concizumab

Concizumab

Product NameConcizumab
CAS1312299-39-0
CBNumberCB28080871
MW0
MOL FileMol file
MSDS FileSDS

Chemical Properties

form	Liquid
color	Colorless to light yellow
FDA UNII	68603V9EAF

Concizumab Price

Product number	Packaging	Price	Product description	Buy
ChemScene CS-0620996	1mg	$379	Concizumab 95.00%	Buy
ChemScene CS-0620996	5mg	$986	Concizumab 95.00%	Buy
ChemScene CS-0620996	10mg	$1582	Concizumab 95.00%	Buy
Biorbyt Ltd orb1290225	100μg	$280	Concizumab >95%	Buy
Biorbyt Ltd orb1290225	1mg	$820	Concizumab >95%	Buy

Concizumab Chemical Properties,Usage,Production

Uses

Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia[1][2].

in vivo

Concizumab (i.v./s.c.) blocks the TFPI interaction with the active site of FXa in cynomolgus monkeys^[2].

1.19Pharmacokinetic parameters after intravenous or subcutaneous administration of Concizumab to cynomolgus monkeys^[2].

Parameter	Unit	Estimate	%RSE
CL_L	mL/h/kg	0.14	6.1
V1	mL/kg	33	34
V2	mL/kg	33	-
Q	mL/h/kg	0.12	16
F	%	93	7.7
V_max	μg/h/kg	11	17
K_m	μg/mL	0.54	52
t_1/2(abs)	h	72	32

CL_L: the linear part of the clearance.
V1: the volume of the central compartment.
V2: the volume of the peripheral compartment.
V_max: the maximum amount of anti-TFPI cleared per time unit via binding to TFPI.
K_m: the concentration at which the target mediated elimination rate is 50% of the maximum value (Vmax).
T_1/2(abs): the absorption half-life, describing the rate of absorption after sc administration.
%RSE: residual standard error.

Animal Model:	Cynomolgus monkeys (target mediated drug disposition (TMDD) model)^[2].
Dosage:	20mg/kg or 200 mg/kg
Administration:	Intravenous injection/subcutaneous injection
Result:	Showed a high bioavailability (93%) and the absorption half-life is estimated to be 72 h.

References

[1] Kjalke M, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021 Jul;19(7):1687-1696. DOI:10.1111/jth.15323
[2] Agers H, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014 Jun 2;56:65-9. DOI:10.1016/j.ejps.2014.02.009

Preparation Products And Raw materials

Concizumab Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Shanghai YuanYe Biotechnology Co., Ltd.	15026964105	2881489226@qq.com	China	87240	60
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	7996	62
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1577	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10302	58
Beijing Jin Ming Biotechnology Co., Ltd.	010-60605840	psaitong@jm-bio.com	China	27626	58
TargetMol Chemicals Inc.	4008200310 15002144251	marketing@tsbiochem.com	China	24951	58
Biolab Reagents	027-65279366 18108604356	products@biolabreagent.com	China	9864	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 086-15871494362 13720134139	orders@jknbiochem.com	China	7284	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11963	58
Wuhan Acumen Bio-Technology Co.,ltd	027-027-16602739303 16602739303	673003916@qq.com	China	4622	58

1312299-39-0, ConcizumabRelated Search

Send Inquiry